Selected Toxicities of Targeted Therapies: Presentation and Management

被引：7
|
作者：
Kollmannsberger, Christian [1 ]
Mitchell, Teresa [1 ]
机构：
[1] British Columbia Canc Agcy, Vancouver Canc Ctr, Div Med Oncol, Vancouver, BC V5Z 4E6, Canada
来源：
SEMINARS IN ONCOLOGY | 2013年 / 40卷 / 04期
关键词：
RENAL-CELL CARCINOMA; ENDOTHELIAL GROWTH-FACTOR; INTERFERON-ALPHA; FACTOR RECEPTOR; SUNITINIB; EFFICACY; HYPERTENSION; EVEROLIMUS; TEMSIROLIMUS; BEVACIZUMAB;
D O I：
10.1053/j.seminoncol.2013.05.011
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The introduction of targeted therapy has changed the landscape of metastatic renal cell carcinoma (mRCC) but has also brought challenges. One such challenge of treating this chronic disease is long-term therapy, which produces ongoing toxicity. Knowledge of the spectrum of toxicity from targeted therapy and appropriate and timely intervention is required to maintain adequate dosing required for optimal outcome. This article addresses some of the major toxicities of newer agents in RCC and discusses management strategies. (C) 2013 Elsevier Inc. All rights reserved.
引用
收藏
页码：499 / 510
页数：12
相关论文
共 50 条
  • [21] Targeted Agents: Management of Dermatologic Toxicities
    Burtness, Barbara
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2014, 12 (5.5): : 793 - 796
  • [22] Management of toxicities associated with targeted therapies for acute myeloid leukemia: when to push through and when to stop
    Wang, Eunice S.
    Baron, Jeffrey
    HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2020, (01) : 57 - 66
  • [23] The toxicities of modern targeted therapies—learning from the price of progress
    Francis J. Giles
    Targeted Oncology, 2009, 4 : 65 - 66
  • [24] Side Effects and Toxicities of Targeted Therapies in Stage IV Melanoma
    Ascierto, Paolo A.
    Bastholt, Lars
    Hersey, Peter
    Cinat, Gabriela
    Eggermont, Alexander M. M.
    Hauschild, Axel
    Espinosa, Enrique
    Robert, Caroline
    AMERICAN JOURNAL OF THERAPEUTICS, 2015, 22 (01) : 44 - 53
  • [25] Gastrointestinal toxicities from targeted therapies: measurement, duration and impact
    Bossi, Paolo
    Lucchesi, Maurizio
    Antonuzzo, Andrea
    CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE, 2015, 9 (02) : 163 - 167
  • [26] TALQUETAMAB SKIN TOXICITIES: PRESENTATION AND MANAGEMENT GUIDELINES
    Catamero, Donna
    Purcell, Kiah
    Urena, Annel
    Ray, Chloe
    Feuer, Julia
    Leon, Yan
    ONCOLOGY NURSING FORUM, 2024, 51 (02)
  • [27] Cutaneous toxicities of new targeted cancer therapies: must know for diagnosis, management, and patient-proxy empowerment
    McFarlane, Thomas
    Rehman, Noor
    Wang, Katie
    Lee, Jenny
    Carter, Caitlin
    ANNALS OF PALLIATIVE MEDICINE, 2020, 9 (03) : 1296 - +
  • [28] Management of targeted therapies in hemodialysis patients
    Janus, Nicolas
    Launay-Vacher, Vincent
    Deray, Gilbert
    Islam, Mohamed Shariful
    Thyss, Antoine
    Thariat, Juliette
    BULLETIN DU CANCER, 2012, 99 (03) : 381 - 388
  • [29] Management of ECD: the era of targeted therapies
    Abla, Oussama
    BLOOD, 2020, 135 (22) : 1919 - 1920
  • [30] Targeted therapies in the management of Colorectal cancer
    Maughan, Tim
    JOURNAL OF MEDICAL GENETICS, 2011, 48 : S26 - S26
12345